» Articles » PMID: 35957547

Hepatocellular Carcinoma Incidence is Decreasing in Korea but Increasing in the Very Elderly

Overview
Specialty Gastroenterology
Date 2022 Aug 12
PMID 35957547
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: A comprehensive analysis of trends in the incidence of hepatocellular carcinoma (HCC) is important for planning public health initiatives. We aimed to analyze the trends in HCC incidence in South Korea over 10 years and to predict the incidence for the year 2028.

Methods: Data from patients with newly diagnosed HCC between 2008 and 2018 were obtained from Korean National Health Insurance Service database. Age-standardized incidence rates (ASRs) were calculated to compare HCC incidence. A poisson regression model was used to predict the future incidence of HCC.

Results: The average crude incidence rate (CR) was 22.4 per 100,000 person-years, and the average ASR was 17.6 per 100,000 person-years between 2008 and 2018. The CR (from 23.9 to 21.2 per 100,000 person-years) and ASR (from 21.9 to 14.3 per 100,000 person-years) of HCC incidence decreased during the past ten years in all age groups, except in the elderly. The ASR of patients aged ≥80 years increased significantly (from 70.0 to 160.2/100,000 person-years; average annual percent change, +9.00%; P<0.001). The estimated CR (17.9 per 100,000 person-years) and ASR (9.7 per 100,000 person-years) of HCC incidence in 2028 was declined, but the number of HCC patients aged ≥80 years in 2028 will be quadruple greater than the number of HCC patients in 2008 (from 521 to 2,055), comprising 21.3% of all HCC patients in 2028.

Conclusion: The ASRs of HCC in Korea have gradually declined over the past 10 years, but the number, CR, and ASR are increasing in patients aged ≥80 years.

Citing Articles

A Prospective, Multicenter, Randomized, Noninferiority Trial of Stopad Versus Tachosil for Hemostasis After Liver Resection.

Lim S, Choi G, Lim J, Han H, Yoon Y, Lee H Cancers (Basel). 2025; 17(5).

PMID: 40075603 PMC: 11898775. DOI: 10.3390/cancers17050757.


Albumin-Bilirubin Grade as a Valuable Predictor of Recurrence and Prognosis in Patients with Hepatocellular Carcinoma Following Radiofrequency Ablation.

Lee C, You G, Jo H, Jun C, Cho E, Kim I Cancers (Basel). 2025; 16(24.

PMID: 39766066 PMC: 11674869. DOI: 10.3390/cancers16244167.


Peripheral immune signatures associated with the risk of hepatocarcinogenesis in cirrhotic Egyptian HCV patients before and after treatment with direct-acting antivirals.

El-Shenawy R, Moustafa R, Helmy N, El-Abd Y, Tabll A, Elesnawy Y Virol J. 2024; 21(1):293.

PMID: 39548562 PMC: 11566392. DOI: 10.1186/s12985-024-02551-3.


Current Insights into Molecular Mechanisms and Potential Biomarkers for Treating Radiation-Induced Liver Damage.

Saha B, Pallatt S, Banerjee A, Banerjee A, Pathak R, Pathak S Cells. 2024; 13(18.

PMID: 39329744 PMC: 11429644. DOI: 10.3390/cells13181560.


Diagnostic performance of new BAST score versus FIB-4 index in predicating of the liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease.

Helal E, Elgebaly F, Mousa N, Elbaz S, Abdelsalam M, Abdelkader E Eur J Med Res. 2024; 29(1):459.

PMID: 39272195 PMC: 11401269. DOI: 10.1186/s40001-024-02032-x.


References
1.
Rawla P, Sunkara T, Muralidharan P, Raj J . Update in global trends and aetiology of hepatocellular carcinoma. Contemp Oncol (Pozn). 2018; 22(3):141-150. PMC: 6238087. DOI: 10.5114/wo.2018.78941. View

2.
Cox A, El-Sayed M, Kao J, Lazarus J, Lemoine M, Lok A . Progress towards elimination goals for viral hepatitis. Nat Rev Gastroenterol Hepatol. 2020; 17(9):533-542. PMC: 7376316. DOI: 10.1038/s41575-020-0332-6. View

3.
Anyiwe K, Qiao Y, De P, Yoshida E, Earle C, Thein H . Effect of socioeconomic status on hepatocellular carcinoma incidence and stage at diagnosis, a population-based cohort study. Liver Int. 2015; 36(6):902-10. DOI: 10.1111/liv.12982. View

4.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

5.
Shiels M, OBrien T . Recent Decline in Hepatocellular Carcinoma Rates in the United States. Gastroenterology. 2020; 158(5):1503-1505.e2. PMC: 7146982. DOI: 10.1053/j.gastro.2019.12.030. View